鲁抗医药：2025年净利同比预减63.26%-72.13%

Core Viewpoint - Lu Kang Pharmaceutical (600789.SH) expects a significant decline in net profit for the fiscal year 2025, projecting a range of 110 million to 145 million yuan, which represents a year-on-year decrease of 63.26% to 72.13% [1] Group 1: Financial Performance - The anticipated net profit for 2025 is estimated to be between 110 million and 145 million yuan [1] - This projection indicates a substantial decrease in profitability compared to the previous year [1] Group 2: Reasons for Performance Change - The decline in profit is attributed to several factors, including the previous year's substantial asset disposal gains from the transfer of land in the southern plant area [1] - Market demand has slowed down, and price reductions due to centralized procurement have put pressure on both volume and pricing [1] - Increased amortization of research and technical assets has also contributed to the financial downturn [1]